PHI with Nasal polypectomy
How does this condition affect your private health insurance?
Nasal polyp surgery, typically Functional Endoscopic Sinus Surgery (FESS), is a procedure to remove benign growths (nasal polyps) from the nasal passages and sinuses. These polyps can cause chronic nasal obstruction, reduced sense of smell, recurrent infections, and facial pain. The surgery aims to restore normal breathing, improve olfaction, and reduce inflammation. Performed endoscopically, it is minimally invasive. While effective in alleviating symptoms, nasal polyps frequently recur, especially in individuals with underlying conditions, often necessitating ongoing medical management or repeat procedures to maintain relief and quality of life.
PKV Risk Assessment
However, some specialized PHI providers may insure you with a surcharge of up to 20%.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several months to years before surgical intervention.
Duration of Illness (Lifetime)
Chronic, often requiring ongoing medical management and potential for recurrence over a lifetime.
Cost of Treatment (Initial)
Typically several thousand to tens of thousands of USD/EUR, depending on the region, facility, and insurance coverage.
Cost of Treatment (Lifetime)
Significantly higher than first occurrence due to potential for recurrence, follow-up care, and ongoing medical management, potentially reaching tens of thousands to over a hundred thousand USD/EUR.
Mortality Rate
Extremely low, less than 0.01% for modern endoscopic surgery.
Risk of Secondary Damages
Moderate for minor complications (e.g., temporary bleeding, infection, altered sense of smell, discomfort). Low for serious complications (e.g., cerebrospinal fluid leak, orbital injury, permanent vision changes).
Probability of Full Recovery
High for immediate symptom improvement post-surgery (e.g., improved breathing, smell). However, complete, lifelong recovery without recurrence of polyps is moderate to low, as polyps frequently recur necessitating further management.
Underlying Disease Risk
High, commonly associated with allergic rhinitis (20-40%), asthma (20-50%), aspirin-exacerbated respiratory disease (AERD, 5-15%), and sometimes cystic fibrosis.